Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial
In the version of the article initially published, in Fig. 3b, the Aleniglipron 120 mg column initially listed LS mean change as “–12.1” and has been updated to read “–12.7,” while in Fig. 4, the data was missing from the bottom-right panel, and all arrows were missing from the “Vomiting” panels. Figures 3 and 4 have now been corrected in the HTML and PDF versions of the article.
Authors
- Blai Coll
- Ildiko Lingvay (ORCID: https://orcid.org/0000-0001-7006-7401)
- Ania M. Jastreboff (ORCID: https://orcid.org/0000-0003-1446-0991)
- Julio Rosenstock (ORCID: https://orcid.org/0000-0001-8324-3275)
- Andrés Acosta (ORCID: https://orcid.org/0000-0003-2286-489X)
- Melissa Choi
- HUIBIN YUE
- J. Butcher
- Antonio Civitarese
- Thomas C. Blevins
- Lisa Connery
- Robert Kushner
- Timothy Smith
- on behalf of the ACCESS Trial Investigators
- FAITH L. HOLMES
- Aline Barth
- Mike Ke Liu
- Donna Ryan
- Yao Li
Institutions
- Pennington Biomedical Research Center (US)
- Northwestern University (US)
- Mayo Clinic (US)
- Yale University (US)
- Rapt Therapeutics (United States) (US)
- Alliance for Multispecialty Research (United States) (US)
- Irene W. and C.B. Pennington Foundation (US)
- Mayo Clinic in Arizona (US)
- Texas Diabetes & Endocrinology (US)
- TRIA Orthopaedic Center (US)
- NeuroMetrix (United States) (US)
- Mayo Clinic in Florida (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Nature Medicine
- Published
- 2026-06-24
- DOI
- https://doi.org/10.1038/s41591-026-04532-1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00